索马鲁肽

Description

Semaglutide · CAS 910463-68-2 · C187H291N45O59. UNII 53AXN4NNHX. Solubility: <1 mg/mL.

Identification

CAS Registry Number	910463-68-2
PubChem CID	56843331
Molecular formula	C187H291N45O59
UNII (FDA)	53AXN4NNHX

Computed Descriptors

Molecular Weight	4114
XLogP3	-5.8
Hydrogen Bond Donor Count	57
Hydrogen Bond Acceptor Count	63
Rotatable Bond Count	151
Exact Mass	4112.1187318
Monoisotopic Mass	4111.1153770
Topological Polar Surface Area	1650
Heavy Atom Count	291
Formal Charge	0

Physical & Chemical Properties

Solubility	<1 mg/mL

GHS Hazard Classification

Reported hazard statements	H302, H312, H332 (12.5%), H315 (12.5%), H319 (12.5%), H351 (25%), H361 (62.5%), H373 (12.5%)

Documented Uses

• Semaglutide is always intended to be used with a reduced calorie diet and increased physical activity. It is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not intended for use in patients with type 1 diabetes or to treat diabetic ketoacidosis. Semaglutide (available as both
• Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved by the US Food and Drug Administration (FDA) as 3 separate brand name medications—Ozempic®, Wegovy®, and Rybelsus®. Each brand name comes with its own associated indications, preparations, and dosages to consider. Due to the increased complexity involved, special attention is necessary for every FDA-approved indication and current off-label use.
• Semaglutide is a recombinant DNA produced polypeptide analogue of human glucagon-like peptide-1 (GLP-1) which is used in combination with diet and exercise in the therapy of type 2 diabetes either alone or in combination with other antidiabetic agents and more recently in weight loss therapy for adults who are overweight or obese. There have been rare published reports of hepatotoxicity attributed to semaglutide therapy.
• Breast Feeding; Lactation; Milk, Human; Hypoglycemic Agents; Incretins; Glucagon-Like Peptide-1 Agonists; GLP-1 Agonists
• Antidiabetic Agents, Weight Loss Agents
• Take on an empty stomach. For oral use of semaglutide, take 30 minutes before the first meal of the day.

Synonyms

Semaglutide; 910463-68-2; Rybelsus; Ozempic; Wegovy; NN9535; NN 9535; NNC 0113-0217; 53AXN4NNHX; NN-9535; CHEBI:167574; DTXSID101027903; NNC-0113-0217; semaglutida; semaglutidum; Oral Semaglutide

Frequently Asked Questions

What are the CAS number and molecular formula of Semaglutide?

CAS 910463-68-2; molecular formula C187H291N45O59; molecular weight — g/mol.

What other names is Semaglutide known by?

Semaglutide, 910463-68-2, Rybelsus, Ozempic, Wegovy, NN9535.

Is Semaglutide classified as hazardous?

Hazard statements reported: H302, H312, H332, H315, H319.

What are the key physical properties of Semaglutide?

Solubility: <1 mg/mL.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.